Integra LifeSciences Sees Q4 Revenues Of $397M to $403M Vs. Consensus Of $405.48M; Adjusted EPS Of $0.89 to $0.93 Vs. Consensus Of $0.92
Portfolio Pulse from Benzinga Newsdesk
Integra LifeSciences anticipates Q4 revenues to be between $397M and $403M, which is lower than the consensus estimate of $405.48M. The company also expects its adjusted EPS to range from $0.89 to $0.93, around the consensus estimate of $0.92.
October 25, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Integra LifeSciences' lower-than-expected Q4 revenue forecast may negatively impact its stock price. However, its adjusted EPS is expected to be in line with consensus, which could mitigate some of the negative impact.
Integra LifeSciences' Q4 revenue forecast is lower than the consensus estimate, which could lead to a negative market reaction and a potential decrease in the stock price. However, the company's adjusted EPS is expected to be in line with consensus, which could offset some of the negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100